Objectives: This study aims to assess the relationship between the expression of c-Met 5 and the prognosis of high grade glioma patients. 6 Method: The MET proto-oncogene encoded c-Met protein. The gene expression data 7 of 325 patients were downloaded from CGGA. The Oncomine database analysis and 8 the prognosis analysis were conducted. Besides, meta-analysis was also performed to 9 confirm the conclusion. 10 Result: Oncomine database was identified and analyzed and results showed that the 11 MET copy number was obviously higher in glioblastoma than normal tissue 12 consistently (p<0.001). The prognostic analysis of 325 high grade glioma samples 13 showed that high c-Met expression patients had poor overall survival (OS) and 14 progression free survival (PFS) than the low c-Met expression patients dramatically 15 (HR, 2.223; 95% CI: 1.662 to 2.974; P<0.0001 and HR, 2.089; 95% CI: 1.578 to 2.770; 16 P<0.0001). 6 studies involving 503 patients were included in the meta-analysis. The 17 pooled results indicated that the high expression of c-Met was not significantly 18 associated with OS (HR =1.01, 95% CI:0.93-1.09), but strongly connected with shorter 19 PFS (HR =1.92, 95% CI:1.42-2.58, p<0.01). 20 Conclusion: c-Met overexpression has correlation with poor prognosis of high grade 21 glioma patients.
Introduction 25
Glioma is the most common primary central nervous system tumors. Based on WHO 26 classification, it is categorized into four grades. High grade glioma, also known as 27 malignant glioma, included grade III tumors (anaplastic astrocytoma, oligoastrocytoma 28 and oligodendroglioma) and grade IV tumors (glioblastoma) 1 . Glioblastoma (GBM), 29 WHO grade IV gliomas, is the third CNS histological type which is most frequently 30 reported. It is the most malignant and lethal histological type, with annual average age-Zhong 2 31 adjusted incidence being 3.2 per 100,000 population in the United States 2 . It has 32 devastating pathology characteristics and highly invasive biological behavior. 33 Currently, there is no enough efficient therapeutic options to prevent glioblastoma 34 progression. People attempt to use many therapeutic ways to prolong patients' lives, 35 but without much effect. The mainstream of glioblastoma treatment is surgery and 36 adjuvant radiotherapy combined with chemotherapy 3 . However, there is still only 5.5% 37 of Five-Year Relative Survival Rates 2 . People are committed to looking for more 38 effective ways to early identify and treat this disease. However, glioblastoma has 39 diverse molecular characteristics, which has increase the difficulty in elucidating 40 underlying mechanism. Although many molecular characterizations are recognized to 41 be relevant to glioblastoma progression possibly, including PTEN, EGFR, HGF/MET 42 signaling pathway, etc. Great efforts have been paid to gain insight into the genetic 43 develop of glioma, the exact mechanism was still not fully understood. There is no 44 targeted drug have been applied in clinic to prolong patients' survival successfully 4 . 45 The MET proto-oncogene is located on chromosome 7q21-31, encoding c-Met 46 protein. MET gene amplification is associated with poor outcome in many disease 5, 6 . 47 Proto-Oncogene Proteins c-Met is a sort of cell surface protein-tyrosine kinase 48 receptors for its only known ligand HGF. Hepatocyte growth factor (HGF), also called 49 scatter sactor (SF) or hepatopoietin, is a multifunctional cytokine which plays an 50 important role in many cell life activities. This protein is constituted by two chains, Some studies support this opinion 16 , whereas other studies have given the evidence to 71 the contrary to oppose to this view 17 . Hence, in order to confirm the relationship 72 between c-Met overexpression and high grade glioma patients' prognosis, we Studies were considered to be eligible if they met the following criteria: (1) It has 108 been published as original articles. (2) Articles were published as a full paper in English. 109 (3) It is not case reports, reviews, letters or the studies with patients less than 10. (4) 110 All study population was pathologically confirmed as having glioma by radiology or independently. NOS is composed of three parts: subject selection (0-4 points), 130 comparability of subject (0-2 points), and outcome (0-3 points). The total points of 131 study with more than 6 scores were considered to be high quality studies. The 132 assessment scores were showed in Appendix 2. 
133

Outcome definition
Results
153
Oncomine database analysis 154 Oncomine database analysis was conducted to compare the DNA copy number of 155 MET in glioma and normal samples. With the thresholds (fold change: 2; p value: 0.01; 156 gene rank: 10%; data type: DNA), two datasets were identified and analyzed (details 157 showed in Table 2 ). Compared with normal samples, MET copy number in 158 glioblastoma was higher in TCGA distinctly (cases=1531, fold change=1.338, 159 P<0.001), as well as in study Beroukhim Brain (cases=187, fold change=1.199, 160 P<0.001) (cases=187, fold change=1.214, P<0.001) (Figure 2) .
161
Prognostic analysis on transcriptome 162 As shown in Figure 3A , the results showed that patients in the high-MET 163 expressed group had significantly shorter OS than low-MET expressed group (HR, 164 2.223; 95% CI: 1.662 to 2.974; P<0.0001). Also, as Figure 3B , PFS was significantly 165 shorter in the high-MET expressed group (HR, 2.089; 95% CI: 1.578 to 2.770; 166 P<0.0001).
Publication searching results
168
Through database search, we have initially identified 1837 articles and then 490 169 duplicates were excluded. After carefully reading, a total of 6 studies were included in 170 the final meta-analysis. The process of selecting studies was presented in Figure 4 . scores was shown in Appendix 2, which showed these studies had high quality. The 179 characteristics of the included studies were listed in Table 1 . According to the areas mentioned in "Patients and Methods" of each article, we 202 split data into two groups roughly. And then the subgroup analysis based on races was 203 also performed. The results still showed manifest heterogeneity, the I² (86.6% in 204 Mongoloid, 0% in Caucasoid) just slightly decreased. (Figure 8 ) 205 Publication bias 206 Publication bias was analyzed by Begg's Test with a P value of 0.462(P>0.05), by 207 Egger's Test with a P value of 0.056 (P>0.05), which suggested low publication bias 208 among the included studies. (Figure 9) (Figure 10 Compared to small sample research, meta-analysis raises the accuracy and the 240 credibility of the study as well as the conclusion. In order to further probe into this 241 problem, we took this statistical method. Our meta-analysis has enrolled 6 studies, 503 242 patients, to investigate this problem. We finally arrived at a conclusion: the 243 overexpression of c-Met was not strongly associated with overall survival (HR=1.01, 244 95% CI: 0.93-1.09). However, we noticed that Kwak 2015 had high weight in forest 245 plot, which coincided with the results of sensitivity analysis, and deviated so broadly a time-dependent factor to glioblastomas prognosis, which could only be observed in 266 survived more than 8.5 months' patients. However, other articles didn't mention this 267 information. To our disappointment, because we don't have enough data, we can't do 268 more analysis about these problems. More detailed researches are expected to explore 269 the exact role that time factor play in this problem. 270 We also use forest plot to ensure the relationship between c-Met overexpression Zhong 9 271 and progression free survival of glioma patients. Kong 2009 , Liu 2011 , Olmez 2014 was enrolled in the study. The results showed that the overexpression of c-Met was 273 significantly associated with poor PFS (HR =1.92, 95% CI:1.42-2.58). 274 In the following, we tried to find out the sources of heterogeneity by performing 275 subgroup analysis according to races. In the subgroup analysis based on race 276 classification, the heterogeneity just fell down a bit. In Caucasoid group, heterogeneity 277 fell down dramatically (I²=0). In Mongoloid group, the heterogeneity was still high. 278 However, when Krak 2015 was excluded, the result shows low heterogeneity in two 279 groups (0% in Mongoloid, p=0.84; 0% in Caucasoid, p=0.337) . The figure was shown 280 in Appendix 3. The high heterogeneity in direct sequencing is mainly caused by Kwak 281 2015, which deviated from the other studies with high HR and weight. Because of the 282 lack of detailed ethnicity data, this subgroup was simply based on the address of 283 hospital mentioned in the "materials and methods" part of each article, but not the exact 284 race of each patient, which naturally resulted in biased conclusion. It will be too hasty 285 to simply affirm or negate the role of this factor played in final conclusion, more 286 detailed subgroup research should be conducted in the future. 287 Moreover, we have also analyzed publication bias of enrolled studies. According 288 to Begg's test and Egger' test, there was low publication bias among the included 289 studies (p>0.05). This made conclusion more incredible. 290 Our study shows strength as follows: Firstly, this article is the first meta-analysis 291 that investigates the connection between c-Met overexpression and high grade glioma 292 patients survival. Second, this article has performed this diversification analysis, 293 including Oncomine, transcriptome and meta-analysis to strengthen the credibility of 294 conclusion. 295 There were still several limitations in our work. Because of the lack of original 296 information, we can't do more detailed subgroup analysis, like whether 8.5 month could 297 influence the relationship between the expression of c-Met and the prognosis of high 298 grade glioma patients. Significant statistical heterogeneity still existed in the current 299 study. Therefore, in order to evaluate prognostic significance of c-Met more precisely, 300 larger sample sized, multi-center and cohort studies should be performed in the future. 301 In summary, with the foundation of the above analysis, we demonstrated that 
